Kura Oncology/$KURA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kura Oncology
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
- Ticker
- $KURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- San Diego, United States
- Website
- www.kuraoncology.com
Kura Oncology Metrics
BasicAdvanced
$913M
-
-$3.36
0.38
-
Price and volume
Market cap
$913M
Beta
0.38
52-week high
$13.90
52-week low
$7.36
Average daily volume
1.7M
Financial strength
Current ratio
4.733
Quick ratio
4.502
Long term debt to equity
0.391
Total debt to equity
0.505
Interest coverage (TTM)
-224.01%
Profitability
EBITDA (TTM)
-316.799
Gross margin (TTM)
-236.72%
Net profit margin (TTM)
-384.30%
Operating margin (TTM)
-411.90%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-31.30%
Return on equity (TTM)
-167.71%
Valuation
Price to revenue (TTM)
11.73
Price to book
18.84
Price to tangible book (TTM)
18.84
Price to free cash flow (TTM)
-7.714
Free cash flow yield (TTM)
-12.96%
Free cash flow per share (TTM)
-1.33
Growth
Revenue change (TTM)
-7.27%
Earnings per share change (TTM)
48.78%
3-year earnings per share growth (CAGR)
17.92%
10-year earnings per share growth (CAGR)
7.41%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Analyst projections of the future price of Kura Oncology stock.
Bulls say / Bears say
KOMZIFTI net product revenue rose 57% quarter on quarter to $9.1 million in Q2 2026, while new patient starts rose 35% and the drug took a majority share of new starts in its menin-inhibitor class. That is encouraging early evidence of launch uptake. (SEC)
In an ongoing Phase 1 study, ziftomenib plus intensive chemotherapy produced a 96% composite complete response rate and 94% 12-month survival in the newly diagnosed NPM1-mutant cohort. These early results point to potential expansion beyond the current relapsed or refractory setting. (Kyowa Kirin)
Early darlifarnib-plus-cabozantinib data showed a 44% response rate in patients with previously treated renal-cell cancer. If confirmed in larger studies, this could give Kura a second oncology growth driver beyond AML. (The Motley Fool)
KOMZIFTI generated $9.1 million in Q2 product revenue against a $68.3 million net loss, and cash plus short-term investments fell from $667.2 million at year-end 2025 to $519.0 million by June 2026. The company remains reliant on its reserves and expected partner payments to fund development. (SEC)
KOMZIFTI carries a boxed warning for potentially fatal differentiation syndrome, which occurred in 26% of 112 patients in the pivotal study, with two fatal cases. QTc prolongation is another recognised safety risk. (Kura Oncology)
Kura expects topline results from its pivotal frontline Phase 3 trial in 2028, leaving the larger treatment opportunity dependent on a long-dated clinical milestone. The promising frontline response and survival results so far come from a single-arm Phase 1 study, not a controlled comparison. (SEC, Kyowa Kirin)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kura Oncology News
AllArticlesVideos
Funds containing Kura Oncology
Fund name | Fund size | $KURA weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.08% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.08% |
iShares Ageing Population£AGES | $953M | 0.08% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.08% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.